During the last 10 years, multiple signal transduction pathways within cells have been discovered. These pathways have been linked to the regulation of many diverse cellular events such as proliferation, senescence, differentiation and apoptosis. This review will focus upon the many roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway. Recent evidence suggests that signaling by the MAP kinase pathway can both enhance proliferation by increased expression of molecules such as cyclin D1, but also cause growth arrest by increased expression of molecules such as the cyclin kinase inhibitor protein p21
Introduction: MAP kinase historical background
'MAP kinase' was first reported by Sturgill and Ray in 1986. 1 This protein kinase was originally described as a 42-kDa insulin-stimulated protein kinase activity whose tyrosine phosphorylation increased after insulin exposure, and that phosphorylated the cytoskeletal protein MAP-2 (hence 'MAP' kinase). Contemporaneous studies by Boulton and Cobb 2 identified an additional 44-kDa isoform of MAP kinase, which they named ERK1 (extracellular signal regulated kinase). Since many growth factors and mitogens could activate MAP kinase, the acronym for this enzyme has subsequently been considered to denote mitogen-activated protein (MAP) kinase. In the following years, additional studies demonstrated that the p42/p44 MAP kinases regulated another protein kinase activity (p90 rsk ), 3 and that they were themselves regulated by a protein kinase activity originally designated MKK (MAP kinase kinase). 4, 5 MKK phosphorylates the MAP kinases on tyrosine and threonine residues and became the first biochemically charac- terized dual specificity (threonine/tyrosine) protein kinase. [4] [5] [6] The use of the nomenclature MAPKK/MKK has declined, and this enzyme is more frequently referred to as MEK (mitogen activated/extracellular regulated kinase). Shortly after the discovery of MEK, a second isoform of this enzyme was identified (MEK1 and MEK2).
7 MEK1/2 were also found to be regulated by reversible phosphorylation, and within 6 months of the discovery of MEK2, the protein kinase responsible for catalyzing MEK1/2 activation was discovered, the proto-oncogene Raf-1. 8, 9 Raf-1 is a member of a family of serine-threonine protein kinases termed Raf-1, B-Raf and A-Raf. [10] [11] [12] Each protein consists of an NH 2 -terminal domain (termed CR1), a COOH-terminal catalytic domain (termed CR3), and a central domain that is heavily phosphorylated in vivo (termed CR2). All 'Raf' family members can phsophorylate and activate MEK1/2, although the relative ability of each member to catalyze this reaction varies (B-RAF Ͼ Raf-1 Ͼ A-RAF). 13, 14 Seminal studies by the laboratories of Wolfman and Wigler demonstrated that the CR1 domain of Raf-1 could reversibly interact with the Ras proto-oncogene in the plasma membrane. 15, 16 The ability of Raf-1 to associate with Ras was dependent upon the Ras molecule being in the GTP-bound state. Studies from the laboratories of Hancock, Marshall, and Sturgill demonstrated that the ability of Raf-1 to be activated depended upon Raf-1 translocation to the plasma membrane. [17] [18] [19] The regulation of Raf-1 activity appears to be very complex, with several mechanisms co-ordinately regulating activity when in the plasma membrane environment. McCormick et al have demonstrated that association of Raf-1 with Ras is sufficient for partial stimulation of Raf-1 activity. 20 More recently, the binding of 14-3-3 proteins to phospho-serine residues in Raf-1 have been suggested to be a key factor in Raf-1 activation. 20a,20b Additionally, Bell and colleagues suggested that lipid second messengers such as phosphatidic acid may be able to bind to Raf-1 and play a role in the activation process. 21 Other investigators have suggested that another lipid second messenger, ceramide, may also be able to play a role in Raf-1 activation, 22, 23 although this is disputed. 24, 25 Data from the laboratories of Sturgill, Morrison, and Marshall have suggested that protein serine/threonine and tyrosine phosphorylations play a role increasing Raf-1 activity when in the plasma membrane environment. [26] [27] [28] Several other studies have also suggested that PKC (protein kinase C) isoforms can directly regulate Raf-1 activity. 29, 30 Phorbol esters and the macro-cyclic lactone bryostatin 1 can activate PKC, and have been shown to activate Raf-1 and the MAP kinase cascade in many cell types. 31, 32 Since phorbol ester-mediated downregulation of PKC blocks the abilities of some agonists, eg platelet-derived growth factor (PDGF), but not others, eg epidermal growth At the same time that Raf-1 was shown to associate with Ras, the laboratories of Schlessinger and Pawson demonstrated that growth factors, via their plasma membrane receptors, stimulate GTP for GDP exchange in Ras using guanine nucleotide exchange factors. 37, 38 Thus, over an interval of ෂ9 years, a pathway was delineated from plasma membrane growth factor receptors, through guanine nucleotide exchange factors and the Ras proto-oncogene, to the Raf-1/MEK/MAP kinase/p90 rsk MAP kinase pathway (Figure 1 ). During this period of time, other studies had begun to link growth factor induced MAP kinase and p90 rsk activations to the ability of these mitogens to regulate transcription factor activities within the nucleus. 39, 40 The relative ability of MAP kinase signaling to mediate increased activity of a variety of transcription factors is still under intensive study, potentially because it appears that many signaling pathways under the control of mitogens, eg c-Jun NH 2 -terminal kinase and p38-reactivating kinase pathways, can co-ordinately regulate transcription factor activities and gene expression along with the classical MAP kinase pathway in an agonist and cell-type specific manner.
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Figure 1
The MAP kinase cascade.
An overview for the role of the MAP kinase pathway in proliferation and differentiation signaling
Initial observations suggested that signaling by the MAP kinase pathway was intimately involved in the abilities of growth factors to stimulate proliferation. 45 Indeed, for several years the predominantly accepted view of signaling through the MAP kinase cascade based on studies with established fibroblastoid and transformed cell models was that its activation promotes proliferation, and the greater the activation, the greater the proliferative response. For example, in NIH 3T3 fibroblasts, transformation with either the v-Ha-Ras oncogene or the v-Raf oncogene caused constitutive activation of the MAP kinase cascade and increased proliferation. 46, 47 In NIH 3T3 cells, expression of a constitutively active form of MEK1 also caused constitutive activation of the MAP kinase cascade and increased proliferation. 48 The positive role of MAP kinase activation in cell cycle progression may be linked to increased expression of cyclin molecules, eg cyclin D1. 48a,48b In leukemic cells, similar observations have been made. For example, several studies have demonstrated that stem cell factor (SCF) and/or granulocyte-macrophage colony-stimulating factor (GM-CSF) can stimulate MAP kinase activity in myeloid and lymphoid leukemia cells, leading to increased proliferation. 49, 51 In agreement with increased MAP kinase activity correlating with increased transformation and proliferation, elevated basal levels of MAP kinase activity are frequently found in acute myelogenous leukemia cells. 52 However, more defined studies examining the extent and duration of MAP kinase activation, are now beginning to show that a simplistic view of increased activation of MAP kinase equating with increased proliferation is not necessarily valid.
One example of such a discrepancy can be found in the case of PC12 pheochromocytoma cells, in which the role of MAP kinase signaling appears to conflict with the conventional view linking increased activity to enhanced proliferation. It was known that exposure of PC12 pheochromocytoma cells to EGF stimulates their proliferation. In contrast, exposure of these cells to nerve growth factor (NGF) was shown to inhibit proliferation and cause a differentiation response. 53, 54 Several groups, including Cohen and co-workers, then noted that whereas EGF induces an acute phasic activation of the MAP kinase pathway, NGF increases MAP kinase activity over a prolonged time period. [53] [54] [55] Studies by Marshall et al confirmed that prolonged signaling via the MAP kinase pathway was essential to the ability of NGF to induce differentiation, and Decker et al have argued that the ability of NGF to cause growth arrest via MAP kinase is dependent upon its ability to increase expression of the cyclin-dependent kinase inhibitor protein (CKI) p21
. [55] [56] [57] [58] Many leukemic cells types behave in a similar manner to PC12 cells when exposed to phorbol esters. For example, Ahn et al 59 demonstrated that phorbol esters cause growth arrest and differentiation in megakaryocytes via activation of classical PKC isoforms. These enzymes cause prolonged activation of the MAP kinase pathway, leading to terminal differentiation. Exposure of myeloid leukemia cells to phorbol esters can also increase p21
Cip-1/MDA6/WAF1 expression, via the MAP kinase pathway. 60 However, of note is that inhibition of PKC function in megakaryocytes promotes differentiation towards an erythroid lineage, suggesting that perturbations in PKC signaling, potentially via downstream recruitment of MAP kinase, can lead to a switch between specific differentiation pathways. 61 Similarly, other studies have suggested that increased or decreased MAPK signaling can influence T cell differentiation between either a CD4 or CD8 expressing cell lineage. 62 In nonleukemic cells, several groups have demonstrated that MAPK signaling can both promote and inhibit adipogenesis and myogenesis in pre-adipocytes and myoblasts, respectively, in a time and context-dependent manner. [63] [64] [65] [66] Thus in some established cell systems, constitutive elevation of MAP kinase activity can stimulate proliferation, whereas in others it triggers increased p21
Cip-1/MDA6/WAF1 levels, cell cycle arrest, and cellular maturation. In contrast, in other cell types, prolonged inhibition of the MAP kinase pathway may also promote maturation and lead to increased p21
Cip-1/MDA6/WAF1 expression.
A possible explanation for at least some of these divergent observations can be found in studies using A431 squamous carcinoma cells. In these cells, exposure to EGF in the dose range 2-100 ng/ml can cause a prolonged activation of the MAP kinase pathway, induction of p21
Cip-1/MDA6/WAF1 , and cell cycle arrest. [67] [68] [69] In contrast, lower concentrations cause less MAPK activation and increase proliferation. In agreement with a pivotal role for EGF-dependent p21
Cip-1/MDA6/WAF1 expression in this process, expression of antisense p21
mRNA in A431 cells causes a mitogenic response to 2-100 ng/ml EGF, ie this growth factor can no longer up-regulate p21
Cip-1/MDA6/WAF1 protein levels. Studies from our own laboratory have also suggested that the relative ability of MAP kinase signaling to increase p21
Cip-1/MDA6/WAF1 expression declines in HepG2 hepatoblastoma cells relative to the unimpaired response noted in primary hepatocytes (P Dent, unpublished data). These data may explain divergent responses to MAP kinase activation between individual cell types. For example, in those cells in which prolonged MAP kinase activation induces p21
Cip-1/MDA6/WAF1 expression, G1 arrest and cellular differentiation may ensue. Conversely, in cells which do not up-regulate p21
Cip-1/MDA6/WAF1 in response to this stimulus, MAP kinase activation may lead to cellular proliferation. It is conceivable that such interactions may reflect the cell type, or represent a function of the transformation state of the cell.
Recently, studies performed in mouse embryonic fibroblasts and in primary rat hepatocytes have demonstrated definitively that an acute phasic activation of the MAP kinase pathway promotes proliferation whereas prolonged activation of the pathway promotes cell cycle arrest. [70] [71] [72] In studies by McMahon and Land, mouse embryonic fibroblasts which were p21−/− did not arrest in response to prolonged MAP kinase activation, suggesting a key role for p21
Cip-1/MDA6/WAF1 in the MAP kinase-mediated cell cycle arrest. 70, 71 In studies by Tombes et al, however, prolonged MAP kinase signaling was observed to increase expression of both p21
Cip-1/MDA6/WAF1 and another CKI protein, p16
INK4a , in primary rat hepatocytes. 72 This suggests that MAP kinase can modify expression of different cassettes of CKI proteins in a cell-type specific manner, which may in turn exert cell type specific functions in mediating cell growth arrest. In general agreement with this hypothesis, prolonged activation of the MAP kinase cascade in transformed embryonic fibroblasts has been shown to reduce p27 Kip-1 and to increase p21 Cip-1/MDA6/WAF1 protein levels, 70 whereas in other cell lines it can increase the levels of both proteins. 73 The expression/functionality of transcription factors downstream of MAP kinase will presumably modify the ability of MAP kinase signaling to regulate the p21
promoter. The best described transcriptional regulator of the p21
Cip-1/MDA6/WAF1 promoter is the tumor suppressor p53. 74 However MAP kinase signaling can increase p21
Cip-1/MDA6/WAF1 protein levels in many tumor cells which express non-functional p53, or do not express p53 at all. [67] [68] [69] 73, 74 These data tend to discount p53 as an essential mediator of the MAP kinase-dependent increase in p21 Cip-1/MDA6/WAF1 levels in all cell types. Several other transcription factors have also been suggested to regulate the p21
Cip-1/MDA6/WAF1 promoter. For example, Kraft et al suggested that the ability of phorbol esters to increase p21
Cip-1/MDA6/WAF1 expression in U937 monoblasts is mediated through the Sp1 binding sites within the p21
Cip-1/MDA6/WAF1 promoter. 75 In various cell types, other investigators have suggested that the transcription factors Sp3, C/EBP␣, C/EBP␤, Stat1, and p300 may also play a role in this process. [76] [77] [78] [79] [80] Thus the precise transcription factor mediators of MAP kinase signaling to the p21 Cip-1/MDA6/WAF1 promoter are not fully described in any one cell type. Futhermore, based on the several reports showing regulation of p21
Cip-1/MDA6/WAF1 in response to increased or decreased MAP kinase signaling, it is very likely that the roles of transcription factors in regulating p21
Cip-1/MDA6/WAF1 expression may be cell type specific.
The ability to link MAP kinase signaling to regulation of p21
Cip-1/MDA6/WAF1 expression is important from a therapeutic perspective. Several studies have shown that p21−/− cells or cells expressing p21 antisense have increased chemo-and radio-sensitivities, 81, 82 suggesting that the relative ability of a cell to express p21
Cip-1/MDA6/WAF1 will alter its responsiveness to a variety of cytotoxic cellular stresses. Thus, by implication from these studies, a potential strategy to sensitize cells to ionizing radiation or chemotherapeutic agents is via inhibition of the MAP kinase pathway.
The potential roles of protein kinase C and MAP kinase signaling in leukemic cell survival after exposure to cytotoxic drugs
Many studies have shown that exposure of a variety of leukemic cell lines to phorbol esters results in a PKC/MAP kinasedependent differentiation response consisting of increased p21
Cip-1/MDA6/WAF1 expression and cell cycle arrest. 60 Considerable evidence is now emerging that the PKC and the MAP kinase pathway play critical roles in leukemic cell survival after treatment with various chemotherapeutic drugs and/or ionizing radiation. Studies from various laboratories utilizing HL-60 and U937 leukemia cells tend to support the concept of a radio-and chemo-protective role for PKC and MAP kinase signaling. 83, 86 Various lines of evidence suggest that one or more isoforms of PKC oppose the cell death process. For example, inhibitors of PKC are among the most potent inducers of apoptosis in leukemic and other neoplastic cell lines. 87 Conversely, tumorpromoting phorboids such as PMA, which activate PKC when administered acutely, tend to block apoptosis, eg in lymphoid cells exposed to dexamethasone. 88 Interruption of the PKC pathway may also lower the apoptotic threshold for various environmental insults. For example, inhibition of the PKC function by sphingosine or by specific catalytic site inhibitors (eg staurosporine) potentiates neoplastic cell apotosis and the reduction in clonogenicity induced by cytotoxic lipids (eg ceramide), cytotoxic drugs (eg 1-␤-D-arabinofuranosylcytosine (ara-C)), and other stresses (eg ionizing radiation). 86, 89, 90 In addition, pretreatment of leukemic cells with PKC activators such as PMA, which also activate MAP kinase, 66 has the net effect of opposing leukemic cell apoptosis in response to drugs such as topoisomerase inhibitors. 91 The downstream target of PKC responsible for its cytoprotective effect is uncertain, but the MAP kinase pathway, which is known to be activated by PKC 60 represents a plausible candidate. Recently, several lines of evidence have begun to suggest that the MAP kinase pathway is an important component in cytoprotective PKC signaling. Studies from our laboratories have demonstrated that sphingosine, which has been shown to promote apoptosis, 92 also induces a rapid inactivation of the MAP kinase pathway in U937 cells. 93 We found that a similar inactivation of the MAP kinase pathway can be obtained by exposing cells to a relatively specific inhibitor of MEK1 (PD98059, amino methoxyflavone). 93 Treatment of U937 cells with either sphingosine or PD98059 increased the rate of U937 cell apoptosis. Furthermore, using sub-lethal concentrations of these agents we found that interruption of the MAP kinase pathway lowered the apoptotic threshold in leukemic cells (see below). Collectively, these findings raise the possibility that interruption of PKC signaling, or that of its downstream target, the MAP kinase cascade, may render leukemic cells more susceptible to certain forms of druginduced apotosis.
Additional insights into the potential roles of PKC and MAP kinase in the regulation of drug-mediated lethality have arisen from studies involving the nucleoside analog Ara-C. Ara-C is converted intracellularly to its active triphosphate derivative, ara-CTP, which is incorporated into elongating strands of DNA, resulting in interference with chain elongation and promotion of chain termination. 94 Exposure of cells to Ara-C, as well as to other cytotoxic drugs, including VP-16 and cisplatin, results in induction of c-Jun 95 and (in the case of Ara-C), activation of the stress-related SAPK/JNK cascade. 96 Moreover, exposure of leukemic cells to Ara-C results in the generation of the pro-apoptotic lipid second messenger ceramide, 97 and, through reversal of phosphatidylcholine synthase activity, 98 the anti-apoptotic lipid diglyceride. The latter reaction presumably accounts for the ability of Ara-C to increase leukemic cell PKC activity, 99 and ultimately, to activate MAP kinase. 99 Thus, exposure of leukemic cells to Ara-C leads to the generation of lipid messengers that exert opposing effects on cell survival; this raises the possibility that the relative extent to which these signaling molecules are generated determines the cell's ultimate fate. Furthermore, the putative cytoprotective effects of PKC and, by extension MAP kinase, may exert a selflimiting effect on Ara-C-mediated lethality. A corollary of this model is that interventions that reduce net PKC (and/or MAP kinase) activity would be predicted to potentiate Ara-C-related cytotoxicity. In agreement with this hypothesis, we and others have found that pharmacologic agents which directly inhibit PKC (eg staurosporine), 99a down-regulate PKC upon chronic exposure (eg bryostatin 1), or ablate PKC expression (eg PKC antisense oligonucleotides) have all been shown to enhance the lethal actions of Ara-C. 93, 95, 100 Interestingly, in the latter study, ceramide exposure decreased whereas diglyceride exposure increased expression of the anti-apoptotic protein Bcl-2 in leukemic cells. 97, 100 More recently, bryostatin 1 and the PKC inhibitor safingol have been shown to block Ara-Cmediated MAP kinase activation in association with potentiation of leukemic cell apoptosis, effects which have found to be mimicked by the MEK1 inhibitor PD98059. 92, 93, 101 Bryostatin 1 and PD98059 have also been found to promote taxolinduced apoptosis in leukemic cells. 102 Collectively, these findings raise the possibility that interruption of the PKC/MAP kinase pathway facilitates drug-induced apoptosis, perhaps by preventing one or more cytoprotective responses. It should be noted that PKC down-regulation or inhibition of MAP kinase function does not potentiate the cytotoxicity of certain other chemotherapeutic agents (eg epipodophyllotoxins, anthracyclines; Jarvis, Dent, and Grant unpublished), suggesting that the sensitizing actions of PKC/MAP kinase interruption may be drug-specific.
The potential roles of protein kinase C and MAP kinase signaling in leukemic cell survival after exposure to ionizing radiation
The ability of ionizing radiation to activate multiple signal transduction pathways within cells has also been the subject of considerable interest. It has been demonstrated by several laboratories that inhibition of PKC and/or MAP kinase function radiosensitizes fibroblast and epithelial cell types. 69, 103 Conversely, PKC activation has been shown to attenuate ionizing radiation-mediated lethality. 104 The lethal effects of ionizing radiation in some cell types, eg in peripheral lymphoblasts from individuals with Neimann-Pick disease, has been directly attributed to the actions of ceramide. 105 The ability of radiation to activate the stress activated protein (SAP) kinase/cJun NH 2 -terminal kinase (JNK) pathway has been investigated in leukemia cells and demonstrated to be dependent upon activation of sphingomyelinase enzymes. 106 These data suggest that sphingomyelinase enzymes, via the SAP kinase pathway, play key roles in mediating radiation-mediated cytotoxic signals. In contrast, less is known about the mechanisms by which radiation may activate the MAP kinase pathway in leukemic cell systems.
Previous studies have shown that activation of PKC by either phorbol esters or bryostatin 1 shortly before or after irradiation exerts cytoprotective effects toward normal human hematopoietic progenitor cells in vitro and in intact animals in vivo. 107 However, down-regulation of PKC expression by a 24 h pretreatment with bryostatin 1 was found to sensitize malignant HL60 leukemia cells to ionizing radiation. 108 More recently, the ability of radiation to modulate the activity of the MAP kinase pathway in HL60 cells has been examined in detail by our laboratories. Low-dose radiation initially causes a potent activation of the MAP kinase pathway in HL60 cells; however, the overall effect of radiation was to reduce MAP kinase specific activity at later time-points (eg 24-48 h after irradiation). 86 Inhibition of the MAP kinase pathway (eg by the MEK1 inhibitor PD98059) also increases the radiosensitivity of HL60 cells and causes a prolonged G 2 /M arrest (in agreement with data in Ref. 69) . Cells which are arrested in G 2 /M then undergo apoptosis, and the remaining non-apoptotic cells showed a 90% loss of clonogenicity in clonogenic assays; 86 also in general agreement with the capacity of PKC down-regulation to exert a similar effect. 108 Furthermore, over-expression of the anti-apoptotic protein Bcl-2 did not abrogate this potentiating effect. 86 Thus, interruption of PKC signaling, or one of its downstream targets, such as the MAP kinase pathway, appears to lower the apoptotic threshold of leukemic cells in response to ionizing radiation and certain chemotherapeutic agents.
Is p21
Cip-1/MAD6/WAF1 a cytoprotective downstream target of PKC-MAP kinase signaling?
The specific target(s) of PKC and/or MAP kinase responsible for cytoprotectivity remain(s) to be elucidated, although several lines of evidence suggest p21 was blunted, and the cells became radiosensized. 69 This is in general agreement with data demonstrating that fibroblasts from p21
Cip-1/MDA6/WAF1 -null mice lack a radiation-inducible G1/S arrest response and are more radiosensitive than wild-type cells. 82 Human colon carcinoma cells deficient in p21
Cip-1/MDA6/WAF1 also display increased susceptibility to apoptosis induced by various chemotherapeutic agents and ionizing radiation. 110, 111 In these studies, it was postulated that the effect stemmed from the inability of p21
Cip-1/MDA6/WAF1 -deficient cells to undergo G 1 arrest. Conversely, others have shown that enforced expression of p21
Cip-1/MDA6/WAF1 in glioblastoma cells renders these cells less susceptible to the lethal actions of alkylating agents, an effect attributed to enhanced DNA repair mechanisms. 112 In addition, induction of HL60 leukemic cell differentiation by PMA, which has been shown under some circumstances to inhibit drug-induced apoptosis, 91 is characteristically associated with up-regulation of p21
Cip-1/MDA6/WAF1 . 113, 114 Taken together, these findings raise the possibility that interference with p21
Cip-1/MDA6/WAF1 expression/function contributes to the pro-apoptotic actions of interruption of the PKC-MAP kinase pathway. Additional studies will be necessary to determine definitively whether loss of p21
Cip-1/MDA6/WAF1 expression/ function is in fact involved in potentiation of drug-and radiation-induced cell death by inhibition/downregulation of the PKC and/or MAP kinase cascades.
Conclusions
Multiple stimuli can modulate MAP kinase activity. Depending upon the cell type and the duration of the MAP kinase activation, this may cause either increased proliferation or growth arrest and differentiation. Furthermore, inhibition of the MAP kinase pathway may increase the susceptibility of leukemic 86, 90 and carcinoma 69, 108 cells to ionizing radiation and cytotoxic drugs by modulating cell cycle progression and/or by interfering with as yet to be identified downstream cytoprotective events, such as p21
Cip-1MDA6/WAF1 (Figure 2 ). Aside from providing insights into the mechanism(s) governing the cell death responses to tumor cells to ionizing radiation and chemotherapeutic agents, further examination of the MAP kinase pathway could ultimately lead to the development of entirely novel therapeutic strategies in leukemia, as well as in non-hematopoietic malignancies. tute (R01-CA35675) and the Chernow Endowment (to PBF). This manuscript is dedicated to the memory of Mr Donald Cantore Snr who died from non-Hodgkin's lymphoma on 14 May 1998.
